Actively Recruiting
Comparison of Systematic Versus Selective Use of Heparin for Preventing Radial Artery Occlusion After Trans-Radial Catheterization Using Dual-Artery Compression
Led by Olivier F. Bertrand · Updated on 2026-01-26
500
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The trial investigates the prevention of radial artery occlusion following diagnostic trans-radial catheterization. It compares the routine use of heparin, which is the current standard of care, with an elective approach where heparin is not systematically administered. The study aims to assess the benefits and risks of these two strategies using a dual-artery compression system for hemostasis after the procedure. Participants are randomly assigned to one of two groups: one group receives a standard dose of 70-100 IU/kg heparin after a diagnostic trans-radial catheterization along with a dual-artery compression device to control bleeding. The other group undergoes the same catheterization and compression device use but without heparin administration. This design evaluates the necessity of heparin in this setting. During the first 24 hours after the procedure, researchers will measure rates of patent hemostasis, the time needed to achieve hemostasis, and nursing time involvement. Additionally, they will monitor for any complications occurring within 30 days. Participants' progress will be tracked closely to gather data on safety and effectiveness of the two treatments throughout the study duration.
CONDITIONS
Brief Title
Comparison of the Systematic Versus the Selective Use of Heparin for the Prevention of Radial Artery Occlusion
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Any patient referred for a diagnostic transradial catheterization
You will not qualify if you...
- Unable to understand study design or provide informed consent
- Unable to receive antiplatelet therapy with aspirin and/or clopidogrel, prasugrel, or ticagrelor and intravenous anticoagulants derived from heparin or bivalirudin
- Local conditions such as hematoma or pseudo-aneurysms preventing radial or ulnar artery access
- Presence of plethysmographic waveform with simultaneous radial and ulnar occlusive compression precluding evaluation of patent hemostasis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Within 24 hours post-procedure
Participants undergo diagnostic trans-radial catheterization followed by either administration of heparin or no heparin, with hemostasis achieved using a dual-artery compression device.
1 procedure visit and observation within 24 hours
Duration - Up to 30 days
Participants are monitored for complications related to the procedure and hemostasis for up to 30 days after the procedure.
1 follow-up visit within 30 days post-procedure
Trial Site Locations
Total: 1 location
1
IUCPQ
Québec, Quebec, Canada, G1V4G5
Actively Recruiting
Research Team
M
Michele Jadin
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here